微剂量糖尿病药物Ozempic导致体重下降的趋势日益增长,引起了安全关切。 Growing trend of microdosing diabetes drug Ozempic for weight loss raises safety concerns.

Ozempic(糖尿病药物)的减肥趋势日益受欢迎。 The trend of "microdosing" Ozempic, a diabetes medication, for weight loss is growing in popularity. 由Novo Nordisk制作的Ozempic及其对应的Wegovy是经林业发展局批准的2型糖尿病和肥胖症。 Ozempic and its counterpart Wegovy, both made by Novo Nordisk, are FDA-approved for type 2 diabetes and obesity. 虽然微剂量旨在降低成本和副作用,但未经林业发展局批准,缺乏临床支持,造成诸如无效和无控制的糖尿病等风险。 While microdosing aims to reduce costs and side effects, it is not FDA-approved and lacks clinical support, posing risks like ineffectiveness and uncontrolled diabetes.